Expert Analysis

Investigational Antiretroviral Agents for HIV-Infected Patients

Source: CCO Independent Conference Coverage of the 2007 Conference on Retroviruses and Opportunistic Infections*

*CCO is an independent medical education company that provides state-of-the-art medical information to healthcare professionals through conference coverage and other educational programs.

Investigational Antiretroviral Agents for HIV-Infected Patients

Faculty:

Joseph J. Eron, Jr., MD
Daniel R. Kuritzkes, MD
William G. Powderly, MD

CME CREDIT INFORMATION

Release Date: 04/23/07

Expiration Date: 04/22/08

Physicians: maximum of 1.25 AMA PRA Category 1 Credits™

Registered Nurses: 1.3 Nursing CE credits

Pharmacists: 1.3 contact hours (0.13 CEUs)

Status: Please log in to view status

Learning Objectives

Upon completion of this activity, participants should be able to:

Identify agents in new classes of antiretroviral agents
Describe the results of recent studies of investigational antiretroviral agents
Discuss the implications of recent studies of investigational antiretroviral agents for patient management strategies

Topics covered include:

MOTIVATE 1 and 2: Maraviroc Treatment of Highly Treatment–Experienced Patients
The BENCHMRK Studies: Raltegravir in Patients With Triple Class–Resistant HIV
Elvitegravir Noninferior to Comparator PIs in Treatment-Experienced Patients
Resistance to Integrase Inhibitors
Rilpivirine Noninferior to Efavirenz in Treatment-Naive Patients
Agents in Early Development

Disclaimer: The materials published on the Clinical Care Options Web site reflect the views of the reviewers or authors of the CCO material, not those of Clinical Care Options, LLC, the CME provider, or the companies providing educational grants. The materials may discuss uses and dosages for therapeutic products that have not been approved by the United States Food and Drug Administration. A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or using any therapies described in these materials.